WO2001028547A1 - Produits alimentaires utiles dans la prevention et l'amelioration de maladies du metabolisme osseux et medicaments preventifs/therapeutiques pour des maladies du metabolisme osseux comprenant ces produits alimentaires - Google Patents
Produits alimentaires utiles dans la prevention et l'amelioration de maladies du metabolisme osseux et medicaments preventifs/therapeutiques pour des maladies du metabolisme osseux comprenant ces produits alimentaires Download PDFInfo
- Publication number
- WO2001028547A1 WO2001028547A1 PCT/JP2000/007217 JP0007217W WO0128547A1 WO 2001028547 A1 WO2001028547 A1 WO 2001028547A1 JP 0007217 W JP0007217 W JP 0007217W WO 0128547 A1 WO0128547 A1 WO 0128547A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- naphthoquinone
- hydroxy
- culture
- bone
- acid bacteria
- Prior art date
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 43
- 208000029725 Metabolic bone disease Diseases 0.000 title claims abstract description 29
- 230000003449 preventive effect Effects 0.000 title claims abstract description 9
- 239000000463 material Substances 0.000 title description 9
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims abstract description 60
- 241000894006 Bacteria Species 0.000 claims abstract description 56
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 50
- FRASJONUBLZVQX-UHFFFAOYSA-N 1,4-naphthoquinone Chemical compound C1=CC=C2C(=O)C=CC(=O)C2=C1 FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 claims abstract description 39
- -1 naphthoquinone compound Chemical class 0.000 claims abstract description 37
- 229930192627 Naphthoquinone Natural products 0.000 claims abstract description 35
- 235000019260 propionic acid Nutrition 0.000 claims abstract description 30
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims abstract description 30
- 239000004310 lactic acid Substances 0.000 claims abstract description 25
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 25
- 230000011164 ossification Effects 0.000 claims abstract description 24
- KQPYUDDGWXQXHS-UHFFFAOYSA-N juglone Chemical compound O=C1C=CC(=O)C2=C1C=CC=C2O KQPYUDDGWXQXHS-UHFFFAOYSA-N 0.000 claims abstract description 23
- CSFWPUWCSPOLJW-UHFFFAOYSA-N lawsone Chemical compound C1=CC=C2C(=O)C(O)=CC(=O)C2=C1 CSFWPUWCSPOLJW-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- GXDIXDKPIUJGOV-UHFFFAOYSA-N 3-amino-1,4-dioxonaphthalene-2-carboxylic acid Chemical compound C1=CC=C2C(=O)C(N)=C(C(O)=O)C(=O)C2=C1 GXDIXDKPIUJGOV-UHFFFAOYSA-N 0.000 claims abstract description 14
- SVPKNMBRVBMTLB-UHFFFAOYSA-N 2,3-dichloronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(Cl)=C(Cl)C(=O)C2=C1 SVPKNMBRVBMTLB-UHFFFAOYSA-N 0.000 claims abstract description 7
- BFXKZQTYMDMKQR-UHFFFAOYSA-N 5,8-dihydroxy-2-(1-hydroxy-4-methylpent-1-enyl)naphthalene-1,4-dione Chemical compound C1=CC(O)=C2C(=O)C(C(O)=CCC(C)C)=CC(=O)C2=C1O BFXKZQTYMDMKQR-UHFFFAOYSA-N 0.000 claims abstract 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 22
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 241000186429 Propionibacterium Species 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 239000012228 culture supernatant Substances 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 229940126585 therapeutic drug Drugs 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 241000186428 Propionibacterium freudenreichii Species 0.000 claims description 5
- RQNVIKXOOKXAJQ-UHFFFAOYSA-N naphthazarin Chemical compound O=C1C=CC(=O)C2=C1C(O)=CC=C2O RQNVIKXOOKXAJQ-UHFFFAOYSA-N 0.000 claims description 4
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 3
- 241000194035 Lactococcus lactis Species 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 abstract description 29
- 230000004097 bone metabolism Effects 0.000 abstract description 8
- 230000037118 bone strength Effects 0.000 abstract description 4
- 150000002791 naphthoquinones Chemical class 0.000 abstract description 3
- 230000003028 elevating effect Effects 0.000 abstract 1
- OBLNWSCLAYSJJR-UHFFFAOYSA-N Quinoclamin Chemical compound C1=CC=C2C(=O)C(N)=C(Cl)C(=O)C2=C1 OBLNWSCLAYSJJR-UHFFFAOYSA-N 0.000 description 56
- 210000004027 cell Anatomy 0.000 description 47
- 230000000694 effects Effects 0.000 description 40
- 210000002997 osteoclast Anatomy 0.000 description 33
- 210000000963 osteoblast Anatomy 0.000 description 24
- 239000000843 powder Substances 0.000 description 23
- 239000002609 medium Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 229940088594 vitamin Drugs 0.000 description 17
- 229930003231 vitamin Natural products 0.000 description 17
- 235000013343 vitamin Nutrition 0.000 description 17
- 239000011782 vitamin Substances 0.000 description 17
- 230000024279 bone resorption Effects 0.000 description 16
- 208000006386 Bone Resorption Diseases 0.000 description 15
- 210000002798 bone marrow cell Anatomy 0.000 description 15
- 239000011575 calcium Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 12
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 12
- 230000002308 calcification Effects 0.000 description 12
- 229910052791 calcium Inorganic materials 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 231100000135 cytotoxicity Toxicity 0.000 description 11
- 230000003013 cytotoxicity Effects 0.000 description 11
- 150000003722 vitamin derivatives Chemical class 0.000 description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 210000002536 stromal cell Anatomy 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108010046377 Whey Proteins Proteins 0.000 description 6
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 241000194036 Lactococcus Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 102000007544 Whey Proteins Human genes 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000003625 skull Anatomy 0.000 description 5
- 210000002303 tibia Anatomy 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000005862 Whey Substances 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 210000005088 multinucleated cell Anatomy 0.000 description 4
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 4
- 239000012192 staining solution Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 3
- 206010065687 Bone loss Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 229930003448 Vitamin K Natural products 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000019168 vitamin K Nutrition 0.000 description 3
- 239000011712 vitamin K Substances 0.000 description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 description 3
- 229940046010 vitamin k Drugs 0.000 description 3
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 description 2
- BXVSAYBZSGIURM-UHFFFAOYSA-N 2-phenoxy-4h-1,3,2$l^{5}-benzodioxaphosphinine 2-oxide Chemical compound O1CC2=CC=CC=C2OP1(=O)OC1=CC=CC=C1 BXVSAYBZSGIURM-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 101000782236 Bothrops leucurus Thrombin-like enzyme leucurobin Proteins 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 208000008924 Femoral Fractures Diseases 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000192132 Leuconostoc Species 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 229940019700 blood coagulation factors Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001201 calcium accumulation Effects 0.000 description 2
- 239000000512 collagen gel Substances 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000002570 interstitial cell Anatomy 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001721 multinucleated osteoclast Anatomy 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 230000004072 osteoblast differentiation Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000019143 vitamin K2 Nutrition 0.000 description 2
- 239000011728 vitamin K2 Substances 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- 239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VOJUXHHACRXLTD-UHFFFAOYSA-N 1,4-dihydoxynaphthalene-2-carboxylic acid Natural products C1=CC=CC2=C(O)C(C(=O)O)=CC(O)=C21 VOJUXHHACRXLTD-UHFFFAOYSA-N 0.000 description 1
- DCMWNCXCQOZPNC-UHFFFAOYSA-N 1,4-dihydroxy-2h-naphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)(O)CC=C(O)C2=C1 DCMWNCXCQOZPNC-UHFFFAOYSA-N 0.000 description 1
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
- CPBJMKMKNCRKQB-UHFFFAOYSA-N 3,3-bis(4-hydroxy-3-methylphenyl)-2-benzofuran-1-one Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3C(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 CPBJMKMKNCRKQB-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- SARKXLKWFKNUMR-UHFFFAOYSA-N 4-benzamido-5-chloro-2-methylbenzenediazonium;chloride Chemical compound [Cl-].C1=C([N+]#N)C(C)=CC(NC(=O)C=2C=CC=CC=2)=C1Cl SARKXLKWFKNUMR-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000186335 Acidipropionibacterium thoenii Species 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000606215 Bacteroides vulgatus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241001655328 Bifidobacteriales Species 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 241001464974 Cutibacterium avidum Species 0.000 description 1
- 241000522213 Dichilus lebeckioides Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 206010016454 Femur fracture Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- BLUHKGOSFDHHGX-UHFFFAOYSA-N Phytol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C=CO BLUHKGOSFDHHGX-UHFFFAOYSA-N 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 241001228709 Suruga Species 0.000 description 1
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 1
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 1
- HNZBNQYXWOLKBA-UHFFFAOYSA-N Tetrahydrofarnesol Natural products CC(C)CCCC(C)CCCC(C)=CCO HNZBNQYXWOLKBA-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
- IOMLBTHPCVDRHM-UHFFFAOYSA-N [3-[(2,4-dimethylphenyl)carbamoyl]naphthalen-2-yl] dihydrogen phosphate Chemical compound CC1=CC(C)=CC=C1NC(=O)C1=CC2=CC=CC=C2C=C1OP(O)(O)=O IOMLBTHPCVDRHM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- BOTWFXYSPFMFNR-OALUTQOASA-N all-rac-phytol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)=CCO BOTWFXYSPFMFNR-OALUTQOASA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229940037448 calcitonin preparations Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960005431 ipriflavone Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 239000001254 oxidized starch Substances 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- BOTWFXYSPFMFNR-PYDDKJGSSA-N phytol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-PYDDKJGSSA-N 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000018398 positive regulation of bone resorption Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940055009 propionibacterium avidum Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000012488 skeletal system development Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 1
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940010250 vitamin k 2 Drugs 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/61—Propionibacterium
- A23V2400/617—Freudenreichii
Definitions
- the present invention relates to a food and drink and a medicament for preventive treatment useful for prevention and improvement of metabolic bone diseases represented by osteoporosis.
- Bone is not only a supporting tissue of the living body, but also an important tissue that stores various minerals such as calcium and phosphorus, and also plays a role in controlling the minerals of bodily fluids.
- bone tissue bone formation and resorption are constantly active, and old bones are replaced with new bones.
- bone osteoblasts of the osteogenic system and osteoclasts of the bone resorbing system are closely related to each other, and to maintain bone tissue and maintain a constant mineral of body fluids, bone resorption and Repeated bone formation.
- This bone reconstruction is called bone remodeling.
- This remodeling of the bone is regulated in a precise and well-balanced manner by physical factors, hormones, and site forces. However, when this balance is lost and bone resorption exceeds bone formation, bone loss is reduced. Among these pathological bone loss, those with normal bone components are called osteoporosis.
- osteoporosis is one of the health disorders whose numbers are increasing with the aging of the population, especially in postmenopausal women. Osteoporosis is prone to fractures of the femoral neck and cerebrovascular disorders, and is a factor in creating many bedridden elderly people, and is a heavy social burden. Therefore, there is a strong social demand for appropriate treatment for osteoporosis, prevention of deterioration, and establishment of effective prevention methods.
- vitamin D is used as a drug for osteoporosis Agents, calcitonin preparations, bisphosphonate preparations, etc., have been developed and clinically applied. However, the development of a silver bullet has not yet been reached.
- vitamin K which is generally known as a blood coagulation factor
- vitamin ⁇ 2 made agent was released in Japan as a drug for improving bone mass, pain in osteoporosis.
- food material containing vitamin ⁇ or vitamin ⁇ 2 is also on the market Ru Tsutsua.
- the present inventors have conducted extensive searches and research on food materials to solve the above problems, and as a result, have found that oral intake of cultures of propionic acid bacteria and lactic acid bacteria can increase bone mass and bone strength. I found it. They have found that a food containing an effective amount of the culture is effective for preventing or ameliorating a metabolic bone disease represented by osteoporosis. Furthermore, 2-amino-3-carboxy-1,4-naphthoquinone and its analogs contained in the culture promote the differentiation and expression of functions of osteoblasts, while inhibiting the formation of osteoclasts. These compounds were found to be useful as preventive and therapeutic drugs for metabolic bone diseases.
- a food or drink wherein the active ingredient is 2-amino-3-carboxy-1,4-naphthoquinone (1) (hereinafter sometimes referred to as “ACNQ”);
- Lactis (Lactococcus lact is subsp. Lact is)
- the metabolic bone disease is osteoporosis.
- (1 2) or (13) a prophylactic or remedy 13.2-amino-3-hydroxypropyl 1,4-naphthoquinone, 1,4-naphthoquinone, 2 -Hydroxy-1,4-naphthoquinone, 2,3-dichloro-1,4-naphthoquinone, 5-hydroxy-1,4-naphthoquinone, 8-hydroxy-1,4-naphthoquinone, 2- ( ⁇ -Hydroxy- ⁇ -methylpentenyl) -5,8-dihydroxy-1,4_naphthoquinone and naphthoquinone compounds selected from the group consisting of salts thereof, or metabolism of cultures of propionic acid bacteria and / or lactic acid bacteria
- 15. The use of (15), wherein the naphtho
- Figure 1 shows the tibia bone density (mg / cm 2 ) of SD rats after SD rats were allowed to freely ingest purified feed containing 2% or 10% BGS powder for 4 weeks.
- FIG. 3 shows the amount of calcium (mg / g) per dry weight of the rat's femur.
- the bar indicates the standard error of the mean (p ⁇ 0.05).
- Figure 4 shows mouse bone marrow-derived stromal cell line ST-2 cells at various concentrations of AC.
- FIG. 5 is a view showing alkaline phosphatase activity of the cells after culturing for 3 days in the presence of NQ
- FIG. 5 is a view showing the number of viable cells (absorbance at 595 nm) of the cells by MTT assay.
- FIG. 2 is a view showing the influence of Ca accumulation by the combination of Min K 2 , ACNQ, and 1a, 25 (OH) 2 D 3 with ACNQ.
- FIG. 9 is a diagram showing the effect of P accumulation due to the combination with.
- FIG. 4 is a diagram showing cytotoxicity due to the combination of.
- FIG. 9 is a graph showing the effects of ACNQ and vitamin on TRAP-positive multinucleated cells in human bone marrow cell (SaAl-1) culture.
- Figure 10 is a broken when cocultured with osteoblast-like interstitial cells and the mouse-derived bone marrow cells from skull d dY mouse newborn 1 ⁇ , 25 (OH) 2 D 3 or in the AC NQ presence It is a figure which shows the influence which has on a bone cell formation.
- FIG. 11 is a diagram showing osteoclast activity when osteoblast-like stromal cells derived from the skull of neonatal d dY mice and bone marrow cells derived from the same mice were co-cultured in the presence of AC NQ.
- any of the naphthoquinone compound, the culture of propionic acid bacteria, and the culture of lactic acid bacteria can be used for the medicine and food and drink of the present invention.
- 2-amino-3-carboxy-1,4-naphthoquinone (AC) is 2-amino-3-carboxy-1,4-naphthoquinone (AC).
- NQ NQ
- This ACNQ is known to be obtained, for example, from a culture of a propionic acid bacterium (a microorganism belonging to the genus Propionibacterium) (JP-A-07-227207, JP-A-07-289273, JP-A-07-289273). -
- Naphthoquinone compounds other than ACNQ can also be obtained from cultures of propionic acid bacteria (Japanese Patent Application Laid-Open No. 08-98677). These naphthoquinone compounds In addition, it is known that cultures of Bacillus subtilis and propionibacteria have a growth activity of bifidobacteria, but it is not known at all whether or not they have an effect on metabolic bone diseases.
- Propionibacteria include Propionibacterium ⁇ Freudenreich
- Propioni bacterium f reudenreichi i Propionibacterium, Tohenii (P. thoenii), Propionibacterium ascidii, Propionibacterium (acidipropionici)> i)
- Propionibacterium avidum. avidum Propionibacterium '' acnes (P. acnes), Propionibacterium.
- Propionibacterium freudenreich examples include P. freudenreichii IF01424 or P. freudenreichii ATCC 6207.
- Examples of the lactic acid bacteria include bacteria belonging to the genus Lactobacillus, the genus Streptococcus, the genus Lactococcus, and the genus Leuconostoc.
- Lactobacillus for example, Lb.acidophilus
- Streptococcus for example, Str. Thermophilus
- Lactococcus for example, Lc. Lact is subsp. Cremor is> Lc. Lact is subsp. lactis and Leuconostoc include, for example, Leuc. mesenteroides subsp. cremoris, Leuc. lactis and the like.
- Cultures of propionic acid bacteria or lactic acid bacteria can be obtained by known means.
- whey protein concentrate (Whey)
- Protein Concentrate There is a method of culturing propionic acid bacteria in a medium in which minerals and monosaccharides are added to WPC) or its enzymatic degradation product (JP-A-10-304871). Alternatively, bifidobacteria and propionibacteria are used as efficient culture methods for propionibacteria. There is a method of culturing while circulating a culture solution in different culture tanks (JP-A-8-66178). These culture methods can be used in the practice of the present invention. Further, those skilled in the art can change the medium composition, culture conditions and the like (dissolved oxygen concentration and the like) in order to further optimize these known methods.
- the “BGS” of the present invention includes, for example, all cultures of propionibacteria and Z or lactic acid bacteria, culture supernatants, microbial cells, extracts thereof, dry powders thereof, or dilutions thereof. .
- the processing forms of BGS are roughly divided into powder and liquid.
- a skim milk powder or whey powder, raw starch, dextrin, or the like is directly added to the culture medium as an excipient, and the solid content of the culture is adjusted to 30 to 40% by weight, followed by spray drying or culture medium.
- the reducing solution of the excipient are mixed, concentrated until the solid content becomes 30 to 40% by weight, and then spray-dried. Long-term storage is possible by deoxidizing (filling with nitrogen or adding an oxygen scavenger) when filling.
- WPC Whey Protein Isolate
- WPI Whey Protein Isolate
- modified starch as well as dextrin, soluble starch, pretty gum, oxidized starch, starch ester, Starch etc.
- it may be processed into a double-dispersed preparation (0.2% double-dispersed powder) for easy use in foods.
- a naphthoquinone compound can be extracted, purified, and collected from a culture of a propionic acid bacterium (JP-A-07-289273). Fermented products containing naphthoquinone compounds Other microorganisms that produce a product include Bacteroides vulgatus JCM5826T, Bacteroides fragi 1 is ATCC 23745, Bacteroides-genus, Bac i 1 laceae, Enterococci, BacteroJ_daceae, Streptcoccaceae, Enterobacteriaceae, and the like.
- Naphthoquinone compounds can also be obtained by chemical synthesis.
- AC NQ can be obtained by a four-step process using a commercially available 1,4-dihydroxynaphthoic acid as a starting material (Japanese Patent Laid-Open No. 10-36328). .
- Examples of the salt of the naphthoquinone compound include pharmaceutically or food acceptable salts.
- Representative salts include acetate, benzenesulfonate, benzoate, bicarbonate, lactate, and quaterate. However, these are examples, and the present invention is not limited to these salts.
- the naphthoquinone compound used in the present invention may have stereoisomers and optical isomers, and these can be used in the present invention at all.
- the naphthoquinone compound promotes alkaline phosphatase (ALP) activity of osteoblasts, which is an indicator of bone formation, and promotes calcification. It inhibits osteoclast differentiation and maturation, but does not inhibit osteoclast activity and does not show cytotoxicity to osteoclasts.
- these naphthoquinone compounds and cultures are a very unique preventive and therapeutic drug for metabolic bone diseases having both effects of promoting bone formation and suppressing bone resorption, or a food or drink for preventing or improving metabolic bone diseases.
- Bone consists of bone-forming cells such as osteoblasts, bone resorbing cells such as osteoclasts, various stromal cells (fibroblasts, fat cells, reticulocytes) and hematopoietic cells. Bone tissue is constructed under a network in which these cells work together.
- Osteoblasts play a major role in bone formation. In the grown bone, osteoblasts are recruited to the bone resorption fossa by osteoclasts, and osteogenesis is initiated to replace the resorbed bone.
- the osteoblast progenitor cells proliferate actively and gradually acquire the differentiation characteristics of osteoblasts.
- the differentiated and mature osteoblasts cause calcification of the formed bone matrix and complete bone formation.
- ALP the expression of ALP and the increase in its activity, in addition to the synthesis of various substrate proteins.
- ST-2 a bone marrow stromal cell line
- ALP activity an index associated with osteoblast differentiation
- ACNQ promoted osteoblast formation in a concentration-dependent manner up to a concentration of 1 zgZm1 ( Figure 4).
- ACNQ promoted the differentiation of bone marrow stromal cells into osteoblasts in a concentration-dependent manner.
- ACNQ did not show cytotoxicity up to a concentration of 1 xg / mL (Fig. 5).
- SaM-1 retains all the characteristics of osteoblasts and, in the presence of 2 mM
- ACNQ has, 10- 5 M to promote the very low concentrations in bone formation such as 1 0- 7 M, and the concentration Niore ⁇ clear that no cytotoxicity Te and Do ivy.
- Osteoclasts are derived from macrophage-type hematopoietic cells, and are bone resorption cells formed by stimulation of bone resorption factors under the specific environment of bone tissue. By forming osteoclasts in vitro from osteoclast precursor cells present in bone marrow, its function can be analyzed. Culture systems for forming osteoclasts include bone marrow cell culture, co-culture of bone marrow cells and osteoblasts, and co-culture of spleen cells and osteoblasts.
- TRIP labeled enzyme
- TRAP-positive cells formed by a co-culture system of primary osteoblast-like stromal cells derived from skulls of mouse neonates and bone marrow cells of mice were examined.
- ACNQ is
- the effect of NQ on bone resorption system activity was investigated.
- the formation of resorption pits and cytotoxicity on ivory slices in the osteoclast-forming system by co-culture of mouse primary osteoblast-like stromal cells and mouse bone marrow cells were measured.
- ACNQ did not inhibit the bone resorption activity of differentiated and mature osteoclasts (Fig. 11).
- ACNQ is toxic to osteoclasts (Fig. 11). This indicates that ACNQ does not impair its function on differentiated 'mature osteoclasts.
- BGS when taken orally, has the effect of increasing bone mass and increasing bone strength.
- ACNQ which is considered to be one of the main active ingredients, enhances osteoblast formation and promotes bone formation.On the other hand, it inhibits the formation of osteoclasts, but the formed osteoclasts It showed a very unique bone metabolism, such as functioning (having bone resorption activity). It is considered that the bone formation promoting activity of BGS is thought to be due to the combined action of various components in BGS, but most of it is based on the action of AC NQ contained in a trace amount in BGS. Is considered to be no doubt.
- vitamin K which is generally known as a blood coagulation factor
- Vitamins and K 2 share a naphthoquinone skeleton, differ only side chains binding to the 3-position of the backbone, are both the same methyl group attached to the 1-position.
- bi evening Mi emissions is a single compound, vitamin kappa 2, it is more 14 homologues of a number of isoprene bonded to the 3-position, vitamins of the inner isoprene units number 4 (Galley two Rugera Niort) kappa 2 -Only 4 promotes bone formation, inhibits bone resorption and inhibits bone loss.
- Vitamin Ki or results effects examined et al was to bone resorption by the side chain of vitamin kappa 2, the Geranirugera Niort is the side chain of vitamin kappa 2 -4, vitamin kappa 2 -4 comparable osteoclasts A formation inhibitory effect was observed.
- phytol which is a side chain of vitamin, has weak inhibitory activity
- the side chain of vitamin K2 having an isoprene unit of 2 to 7 (excluding 4) showed rather no inhibitory action but rather promoted (Hara).
- K. et al . Bone, 16: 179-184, 1995).
- ACNQ also Suruga have a similarly naphthoquinone skeleton with vitamin K, or K 2 of the present invention, the 2-position of the skeleton is the Amino group and the 3-position is bonded carboxyl group, vitamins or vitamin as discussed above ⁇ 2 of bone metabolic activity in the side chain Considering that they depend on each other, they are considered to be completely different.
- the culture or the naphthoquinone compound promotes bone metabolism, and an effective amount thereof can be added to a daily food for the production of a food useful for preventing or ameliorating osteoporosis.
- the foods to be added are not particularly limited, but preferably, in Japan, special use foods (food for the sick, food for the elderly, foods for specified health use) that are permitted to be labeled for health use or for limited use ). In foreign countries, there are foods approved for health claims.
- the naphthoquinone compound may be used in the food or drink for preventing or ameliorating metabolic bone disease.However, from the viewpoint of safety and health, it is preferable to use a natural product, especially a culture of propionic acid bacteria. preferable.
- the culture is not only the solvent itself, but also the solvent extract, the processed product thereof (for example, a culture solution containing bacterial cells, an extract of the bacterial cells, a supernatant of the culture solution, a concentrate, a dried product, and a diluted product thereof). Etc.).
- a stabilizer such as sodium ascorbate may be added.
- the amount of the culture to be added is calculated from the content of the naphthoquinone compound as the active ingredient (for example, see Reference Example 2).
- the culture may be added, for example, to 0.5 to 10% by weight.
- composition for food and beverage of the present invention may be used alone, but may be used in combination with a pharmaceutically acceptable carrier, and one or more other food nutrients such as vitamins, minerals, and amino acids. You may.
- food-acceptable carriers include binders, excipients, preservatives, coloring agents and the like.
- the naphthoquinone compound and the culture are usually used in the form of a general pharmaceutical composition.
- compositions are prepared using pharmaceutically acceptable carriers such as fillers, bulking agents, binders, humectants, disintegrants, surfactants, diluents such as lubricants, or excipients. Is done.
- pharmaceutically acceptable carriers such as fillers, bulking agents, binders, humectants, disintegrants, surfactants, diluents such as lubricants, or excipients.
- various forms can be selected according to the purpose of treatment. Representative examples include tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, vaginal suppositories, injections (solutions and suspensions), and the like.
- the dosage of the prophylactic / therapeutic drug for metabolic bone disease should be set in consideration of the patient's condition such as age and weight, the administration route, the nature and extent of the disease, etc.
- the amount of the compound is in the range of 0.5 to 10 Omg / kg for oral administration per day. In some cases, lower doses are sufficient, and conversely, higher doses may be required. It can also be administered in 2 to 4 divided doses per day.
- the medicament of the present invention When the medicament of the present invention is administered, calcium is required for bone formation, and thus may be administered in combination with a calcium agent. In addition, it may be administered in combination with a bone resorption inhibitor [eg, active vitamin D 2 , active vitamin D 3 , calcitonin, estrogen, ibriflavone (Osten (trade name)) and the like].
- a bone resorption inhibitor eg, active vitamin D 2 , active vitamin D 3 , calcitonin, estrogen, ibriflavone (Osten (trade name)
- Enzymatic digestion was performed at 50 for 2 hours. During the reaction, the pH was maintained at pH 7.0 with 8N-Na ⁇ H.
- Propionibacterium f reudenreichi i ATCC 6207 strain (an example of a strain number) was previously statically cultured in a TPY medium (see Example 1 of JP-A-7-289273).
- HP LC conditions are as follows
- Multi-electrode electrochemical detector Coulochem ⁇ (ESA, Inc)
- the femur calcium level was significantly higher in the group receiving 10% BGS powder than in the control group, and the group receiving 2% BGS powder was not significant but tended to be higher than the control group. (Figure 3).
- the results of these in vivo studies revealed that ingestion of BGS increased bone density, increased rupture stress, and increased calcium accumulation. In other words, it was revealed that ingestion of BGS promotes bone formation and has the effect of increasing bone mass and strength.
- the medium was replaced with the same medium containing ACNQ, and the cells were further cultured for 3 days. After the culture, the ALP activity of the cells was measured.
- the cells were washed with PBS and fixed with ethanol for 1 minute. 37 Add the enzyme reaction solution at 77 ° C (buffer containing P-nitrophenylphosphate, 0.1 M glycine, lmM MgCl 2 , and 0.1 mM ZnC1, pH 10.5 as substrate). The reaction was carried out at 37 ° C for 30 minutes. The reaction was stopped by adding an equal volume of 0.05 NNaOH. The ALP activity was expressed as 1 U of the amount of p-nitrophenol (measured by absorbance at 415 nm) generated per minute per mg of protein. The protein content was measured using a protein measurement reagent (Bio-Rad Lab.). ACNQ cytotoxicity was measured by MTT assay (Fig. 5).
- the ALP activity of the cells increased in a concentration-dependent manner up to the ACNQ concentration of 1 / igZmL, and reached a peak near the concentration of 1 gZmL (Fig. 4). No cytotoxicity was observed at this peak level of ALP activity (FIG. 5).
- SaM-1 Cultured human osteoblasts (SaM-1) established from the long periosteum of a 20-year-old man obtained during fracture surgery were used. These Sa M-1 cells retained all the characteristics of osteoblasts (Koshihara, Y. et al .: In Vitro Cell. Dev. Biol., 25: 37-43, 1989). S am- 1 is, 2 mM Nohi - in glycerin port phosphate presence, 1 ⁇ , 2 5 ( ⁇ _Ita) depending on the concentration of 2D 3 is known to promote calcification (Koshihara, Y. et al .: Biochem. Biopys. Res. Commun., 145: 65t 657, 1987).
- Ca in the matrix was determined using a kit (calcium) based on the o-cresolphthalein complex exone method (OCPC method) (Gitleman, HJ: Anal. Biochem., 18: 520-531, 1967). It was quantified by C test (1).
- a reaction reagent was prepared by mixing 0.84% ammonium molybdate, 2N-sulfuric acid, and 10% ascorbic acid in a ratio of 3: 3: 1 (volume ratio). After 100 L of the extract extracted in the above Ca measurement was diluted with 800 / L of distilled water, 2.1 ml of the reaction reagent was added, and the mixture was incubated at 45 ° C for 20 minutes. After cooling with water, the reaction solution was measured with an absorbance meter (570 nm) (Fig. 7).
- the released LDH in the culture supernatant was measured to examine the cytotoxicity of ACNQ.
- the culture supernatant was collected on day 32 of the culture, and LDH was measured using a microplate reader (540 nm) after the color reaction.
- Human bone marrow cells obtained during artificial head replacement surgery are subjected to density gradient centrifugation to obtain mononuclear cells.
- the mononuclear cells 1 alpha of 20% ⁇ Ma serum and 10- 8 M, so that the 25 (OH) one containing one D ⁇ - ⁇ medium 8 X 1 0 "cells dowels (079 cnt)
- the cells were inoculated and cultured for 17 days
- the culture medium was replaced twice a week with 1Z2, and ACNQ was added at the beginning.
- stromal cells were removed by treatment with pronase ZEDTA. The next day, the cells were washed with PBS (-), and then fixed with formalin. Formalin-fixed cells were subjected to TRAP staining, and the number of TRAP-positive multinucleated cells in each well was counted. Vitamin K1 was used as a control.
- a primary osteoblast-like interstitial cells and bone marrow cells about 1: 20 cell number Dressings containing a ratio of, with 1 0% FBS added ⁇ , 10- 8 ⁇ 10- 1 ° ⁇ of 1
- the cells were co-cultured for 6 to 8 days in the presence of ⁇ , 25 ( ⁇ H) 2 D 3 .
- ⁇ , 25 ( ⁇ H) 2 D 3 The cells were co-cultured for 6 to 8 days in the presence of ⁇ , 25 ( ⁇ H) 2 D 3 .
- Osteoclasts were differentiated from cells that were positive for TRAP staining and had 3 or more nuclei in the cells.
- the TRAP staining solution is prepared by dissolving 5 mg of substrate (naphthol AS-MX phosphate) and 25 mg of dye (Fast red violet LB salt) in about 0.5 ml of N, N-dimethylformamide.
- substrate naphthol AS-MX phosphate
- dye Fluor Red violet LB salt
- the maximum number of osteoclasts obtained by this method is 4 x 10 cells and the cell size is 100 mm.
- the osteoclast-like multinucleated cells were prepared in 4 X 1 0 3 cells / mL in 1 0% FBS added ⁇ medium, the Ueru containing the ivory slices (9 6 holes), per Ueru 1 0 0 beta 1
- the cells were seeded and cultured at 37 ° C for 2 hours. After the culture, the cells were transferred to 24 or 48 wells containing 0.5 to 1. OmL Nowell's medium. At the same time, various concentrations of AC NQ were added to each well, and cultured at 37 ° C for 24 hours. After culturing, the medium was removed, and the ivory sections were stained for a short time with a malic acid staining solution of Mayer.
- the culture of the propionic acid bacterium and the Z or lactic acid bacterium of the present invention can be added to food, and by ingesting the food, it can be expected to prevent or improve metabolic bone disease, particularly osteoporosis. Also, 2-amino-3-carboxy-1,4-naphthoquinone and derivatives of naphthoquinone contained in the culture are useful as preventive and therapeutic drugs for metabolic bone diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU79473/00A AU780598B2 (en) | 1999-10-19 | 2000-10-18 | Food materials useful in preventing and ameliorating metabolic bone diseases and preventives/remedies for metabolic bone diseases comprising these materials |
US10/110,206 US7709537B1 (en) | 1999-10-19 | 2000-10-18 | Food materials useful in preventing and ameliorating metabolic bone diseases and preventives/remedies for metabolic bone diseases comprising these materials |
CA2388243A CA2388243C (en) | 1999-10-19 | 2000-10-18 | Food materials useful in preventing and ameliorating metabolic bone diseases and preventives/remedies for metabolic bone diseases comprising these materials |
DE60029469T DE60029469T2 (de) | 1999-10-19 | 2000-10-18 | Verwendung von nahrungsmitteln in der prophylaxe und behandlung von stoffwechselbedingten knochenerkrankungen |
JP2001531377A JP4750991B2 (ja) | 1999-10-19 | 2000-10-18 | 代謝性骨疾患の予防および改善に有用な食品素材および該素材の有効成分からなる代謝性骨疾患の予防治療薬 |
EP00969840A EP1230920B1 (en) | 1999-10-19 | 2000-10-18 | Use of food materials in preventing and ameliorating metabolic bone diseases |
US11/295,601 US20060093651A1 (en) | 1999-10-19 | 2005-12-07 | Food materials useful in preventing and ameliorating metabolic bone diseases and preventives/remedies for metabolic bone diseases comprising these materials |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29605399 | 1999-10-19 | ||
JP29605299 | 1999-10-19 | ||
JP11/296053 | 1999-10-19 | ||
JP11/296052 | 1999-10-19 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/295,601 Division US20060093651A1 (en) | 1999-10-19 | 2005-12-07 | Food materials useful in preventing and ameliorating metabolic bone diseases and preventives/remedies for metabolic bone diseases comprising these materials |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001028547A1 true WO2001028547A1 (fr) | 2001-04-26 |
Family
ID=26560520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/007217 WO2001028547A1 (fr) | 1999-10-19 | 2000-10-18 | Produits alimentaires utiles dans la prevention et l'amelioration de maladies du metabolisme osseux et medicaments preventifs/therapeutiques pour des maladies du metabolisme osseux comprenant ces produits alimentaires |
Country Status (11)
Country | Link |
---|---|
US (2) | US7709537B1 (ja) |
EP (1) | EP1230920B1 (ja) |
JP (1) | JP4750991B2 (ja) |
KR (2) | KR100898756B1 (ja) |
CN (1) | CN1187043C (ja) |
AT (1) | ATE333272T1 (ja) |
AU (1) | AU780598B2 (ja) |
CA (1) | CA2388243C (ja) |
DE (1) | DE60029469T2 (ja) |
TW (2) | TWI243673B (ja) |
WO (1) | WO2001028547A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003016544A1 (fr) * | 2001-08-10 | 2003-02-27 | Meiji Dairies Corporation | Procede d'elaboration d'acide 1,4-dihydroxy-2-naphtoique |
JP2004315477A (ja) * | 2003-04-18 | 2004-11-11 | Tokyoto Koreisha Kenkyu Fukushi Shinko Zaidan | 骨吸収抑制剤 |
WO2005099725A1 (ja) * | 2004-04-13 | 2005-10-27 | Meiji Dairies Corporation | 炎症性腸疾患予防および/または治療剤 |
JP2007284449A (ja) * | 2001-08-10 | 2007-11-01 | Meiji Milk Prod Co Ltd | 1,4−ジヒドロキシ−2−ナフトエ酸の製造法 |
WO2008088008A1 (ja) | 2007-01-17 | 2008-07-24 | Meiji Dairies Corporation | 消化管機能異常症予防及び/又は治療剤 |
JP2013515712A (ja) * | 2009-12-23 | 2013-05-09 | ハオマメディカ・リミテッド | 骨粗鬆症の治療 |
KR101342791B1 (ko) | 2012-08-16 | 2013-12-19 | 주식회사 제이케이뉴트라 | 1,4-디히드록시-2-나프토산 생산능을 가지는 락토바실러스 카제이 lp1 균주 및 이의 이용 |
CN111650309A (zh) * | 2020-07-16 | 2020-09-11 | 余文兵 | 一种含脂配方粉中维生素k1的检测方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001028547A1 (fr) * | 1999-10-19 | 2001-04-26 | Meiji Milk Products Co., Ltd | Produits alimentaires utiles dans la prevention et l'amelioration de maladies du metabolisme osseux et medicaments preventifs/therapeutiques pour des maladies du metabolisme osseux comprenant ces produits alimentaires |
EP1946752B1 (en) | 2005-08-26 | 2011-04-20 | Meiji Dairies Corporation | Anti-allergic agent |
US20100247500A1 (en) * | 2007-11-27 | 2010-09-30 | Kakuhei Isawa | Agent and method for improving survivability of lactic acid bacterium, and food composition |
US20120020927A1 (en) * | 2009-04-15 | 2012-01-26 | Danisco A/S | Bacterial Strains Having an Outstanding Ability to Produce Menaquinone |
KR102127108B1 (ko) * | 2018-06-26 | 2020-06-26 | 고려대학교산학협력단 | 프로피오니바크테리움 후레우덴레이키, 이의 배양액 또는 이의 사균체를 유효성분으로 함유하는 골질환의 예방 또는 치료용 조성물 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07289273A (ja) * | 1994-04-26 | 1995-11-07 | Meiji Milk Prod Co Ltd | ナフトキノン誘導体 |
JPH0898677A (ja) * | 1994-04-26 | 1996-04-16 | Meiji Milk Prod Co Ltd | ビフィズス菌増殖促進組成物 |
JPH09194384A (ja) * | 1996-01-19 | 1997-07-29 | Snow Brand Milk Prod Co Ltd | ミネラル吸収促進剤 |
JPH1056959A (ja) * | 1996-08-14 | 1998-03-03 | Yakult Honsha Co Ltd | ビタミンk補給食品および骨粗鬆症予防・治療用食品 |
JP2000256201A (ja) * | 1999-03-02 | 2000-09-19 | Meiji Milk Prod Co Ltd | ビフィズス菌によるオリゴ糖利用能改善剤 |
WO2000060950A1 (en) * | 1999-04-13 | 2000-10-19 | Sigma-Tau Healthscience S.P.A. | Dietary supplement derived from fermented milks for the prevention of osteoporosis |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3011461C2 (de) * | 1980-03-25 | 1986-10-30 | Dr. Madaus & Co, 5000 Köln | Verwendung von Propionibakterien |
US5096718A (en) * | 1982-09-17 | 1992-03-17 | The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University | Preserving foods using metabolites of propionibacteria other than propionic acid |
JPH08126473A (ja) * | 1994-09-08 | 1996-05-21 | Fuji Oil Co Ltd | 油性組成物およびその製法並びにそれを用いた油性被覆菓子 |
GB9613309D0 (en) * | 1996-06-25 | 1996-08-28 | Univ Sheffield | Quinone bacterial inhibitors |
US5989612A (en) * | 1996-10-11 | 1999-11-23 | Rodia Inc. | Foods including antimycotic agent |
JPH10158178A (ja) * | 1996-11-29 | 1998-06-16 | Yakult Honsha Co Ltd | ミネラル吸収促進剤およびミネラル強化剤 |
GB9920578D0 (en) * | 1999-08-31 | 1999-11-03 | Nestle Sa | Composition for maintenance of bone or dental health or treatment of bone or dental disorders |
WO2001028547A1 (fr) * | 1999-10-19 | 2001-04-26 | Meiji Milk Products Co., Ltd | Produits alimentaires utiles dans la prevention et l'amelioration de maladies du metabolisme osseux et medicaments preventifs/therapeutiques pour des maladies du metabolisme osseux comprenant ces produits alimentaires |
-
2000
- 2000-10-18 WO PCT/JP2000/007217 patent/WO2001028547A1/ja active IP Right Grant
- 2000-10-18 AT AT00969840T patent/ATE333272T1/de not_active IP Right Cessation
- 2000-10-18 DE DE60029469T patent/DE60029469T2/de not_active Expired - Lifetime
- 2000-10-18 CA CA2388243A patent/CA2388243C/en not_active Expired - Lifetime
- 2000-10-18 JP JP2001531377A patent/JP4750991B2/ja not_active Expired - Fee Related
- 2000-10-18 CN CNB008145660A patent/CN1187043C/zh not_active Expired - Lifetime
- 2000-10-18 KR KR1020027004619A patent/KR100898756B1/ko active IP Right Grant
- 2000-10-18 AU AU79473/00A patent/AU780598B2/en not_active Expired
- 2000-10-18 EP EP00969840A patent/EP1230920B1/en not_active Expired - Lifetime
- 2000-10-18 KR KR1020067027347A patent/KR100866008B1/ko active IP Right Grant
- 2000-10-18 US US10/110,206 patent/US7709537B1/en not_active Expired - Lifetime
- 2000-10-19 TW TW093127201A patent/TWI243673B/zh not_active IP Right Cessation
- 2000-10-19 TW TW089121955A patent/TWI248359B/zh not_active IP Right Cessation
-
2005
- 2005-12-07 US US11/295,601 patent/US20060093651A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07289273A (ja) * | 1994-04-26 | 1995-11-07 | Meiji Milk Prod Co Ltd | ナフトキノン誘導体 |
JPH0898677A (ja) * | 1994-04-26 | 1996-04-16 | Meiji Milk Prod Co Ltd | ビフィズス菌増殖促進組成物 |
JPH09194384A (ja) * | 1996-01-19 | 1997-07-29 | Snow Brand Milk Prod Co Ltd | ミネラル吸収促進剤 |
JPH1056959A (ja) * | 1996-08-14 | 1998-03-03 | Yakult Honsha Co Ltd | ビタミンk補給食品および骨粗鬆症予防・治療用食品 |
JP2000256201A (ja) * | 1999-03-02 | 2000-09-19 | Meiji Milk Prod Co Ltd | ビフィズス菌によるオリゴ糖利用能改善剤 |
WO2000060950A1 (en) * | 1999-04-13 | 2000-10-19 | Sigma-Tau Healthscience S.P.A. | Dietary supplement derived from fermented milks for the prevention of osteoporosis |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100899615B1 (ko) * | 2001-08-10 | 2009-05-27 | 메이지 데어리즈 코포레이션 | 1,4-디히드록시-2-나프토산의 제조방법 |
CN1312285C (zh) * | 2001-08-10 | 2007-04-25 | 明治乳业株式会社 | 制造1,4-二羟基-2萘甲酸的方法 |
WO2003016544A1 (fr) * | 2001-08-10 | 2003-02-27 | Meiji Dairies Corporation | Procede d'elaboration d'acide 1,4-dihydroxy-2-naphtoique |
US7834061B2 (en) | 2001-08-10 | 2010-11-16 | Meiji Dairies Corporation | Process for producing 1,4-dihydroxy-2-naphthoic acid |
US7629155B2 (en) | 2001-08-10 | 2009-12-08 | Meiji Dairies Corporation | Process for producing 1,4-dihydroxy-2-naphthoic acid |
AU2002323899B2 (en) * | 2001-08-10 | 2007-06-28 | Meiji Dairies Corporation | Process for producing 1,4-dihydroxy -2-naphthoic acid |
JP2007284449A (ja) * | 2001-08-10 | 2007-11-01 | Meiji Milk Prod Co Ltd | 1,4−ジヒドロキシ−2−ナフトエ酸の製造法 |
US8110607B2 (en) | 2001-08-10 | 2012-02-07 | Meiji Co., Ltd. | Process for producing 1,4-dihydroxy-2-naphthoic acid |
US7374915B2 (en) | 2001-08-10 | 2008-05-20 | Meiji Dairies Corporation | Process for producing 1,4-dihydroxy-2-naphthoic acid |
JP4653785B2 (ja) * | 2001-08-10 | 2011-03-16 | 明治乳業株式会社 | 1,4−ジヒドロキシ−2−ナフトエ酸の製造法 |
AU2002323899B9 (en) * | 2001-08-10 | 2003-03-03 | Meiji Dairies Corporation | Process for producing 1,4-dihydroxy -2-naphthoic acid |
JP2004315477A (ja) * | 2003-04-18 | 2004-11-11 | Tokyoto Koreisha Kenkyu Fukushi Shinko Zaidan | 骨吸収抑制剤 |
WO2005099725A1 (ja) * | 2004-04-13 | 2005-10-27 | Meiji Dairies Corporation | 炎症性腸疾患予防および/または治療剤 |
US8025911B2 (en) | 2004-04-13 | 2011-09-27 | Meiji Dairies Corporation | Preventive and/or remedy for inflammatory bowel diseases |
JPWO2005099725A1 (ja) * | 2004-04-13 | 2008-03-06 | 明治乳業株式会社 | 炎症性腸疾患予防および/または治療剤 |
US8241684B2 (en) | 2004-04-13 | 2012-08-14 | Meiji Co., Ltd. | Preventive and/or therapeutic agent for inflammatory bowel diseases |
WO2008088008A1 (ja) | 2007-01-17 | 2008-07-24 | Meiji Dairies Corporation | 消化管機能異常症予防及び/又は治療剤 |
US9675647B2 (en) | 2007-01-17 | 2017-06-13 | Meiji Co., Ltd. | Prophylactic and/or therapeutic agent for functional gastrointestinal disorders |
JP2013515712A (ja) * | 2009-12-23 | 2013-05-09 | ハオマメディカ・リミテッド | 骨粗鬆症の治療 |
KR101342791B1 (ko) | 2012-08-16 | 2013-12-19 | 주식회사 제이케이뉴트라 | 1,4-디히드록시-2-나프토산 생산능을 가지는 락토바실러스 카제이 lp1 균주 및 이의 이용 |
CN111650309A (zh) * | 2020-07-16 | 2020-09-11 | 余文兵 | 一种含脂配方粉中维生素k1的检测方法 |
Also Published As
Publication number | Publication date |
---|---|
TWI248359B (en) | 2006-02-01 |
JP4750991B2 (ja) | 2011-08-17 |
DE60029469T2 (de) | 2007-03-01 |
KR20070011621A (ko) | 2007-01-24 |
EP1230920B1 (en) | 2006-07-19 |
AU780598B2 (en) | 2005-04-07 |
US20060093651A1 (en) | 2006-05-04 |
US7709537B1 (en) | 2010-05-04 |
AU7947300A (en) | 2001-04-30 |
KR100866008B1 (ko) | 2008-10-29 |
KR20020048959A (ko) | 2002-06-24 |
ATE333272T1 (de) | 2006-08-15 |
CN1187043C (zh) | 2005-02-02 |
TWI243673B (en) | 2005-11-21 |
KR100898756B1 (ko) | 2009-05-25 |
CA2388243A1 (en) | 2001-04-26 |
EP1230920A1 (en) | 2002-08-14 |
EP1230920A4 (en) | 2004-09-29 |
TW200509888A (en) | 2005-03-16 |
CN1382043A (zh) | 2002-11-27 |
CA2388243C (en) | 2010-05-04 |
DE60029469D1 (de) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060093651A1 (en) | Food materials useful in preventing and ameliorating metabolic bone diseases and preventives/remedies for metabolic bone diseases comprising these materials | |
JP6852111B2 (ja) | 骨疾患を予防、治療又は軽減するための方法及び組成物 | |
JP5954828B2 (ja) | 皮膚状態の改善用組成物 | |
AU2005232497B2 (en) | Preventive and/or therapeutic agent for inflammatory bowel diseases | |
US20110189149A1 (en) | New Uses of Lactic Acid Bacteria and Bifidobacteria | |
KR20200084817A (ko) | 비만의 예방 또는 치료 효과를 가지는 신규 락토바실러스 람노서스 균주 및 이의 용도 | |
TW201130496A (en) | Dna damage repair promoter for oral application, and elastase activity inhibitor for oral application | |
EP4108249A1 (en) | Composition for treating climacteric disorder comprising lactobacillus gasseri bnr17 | |
EP3626728A1 (en) | Peptide for inhibiting bone resorption | |
EP4049667A1 (en) | Uremic toxin reducing agent | |
KR20120045122A (ko) | 관절염을 포함한 골 질환 예방 및 치료용 조성물 | |
CN111870689A (zh) | 一种纳豆激酶在治疗骨质疏松药物中的应用 | |
KR20140144496A (ko) | 인슐린 저항성 개선 효능을 가지는 락토바실러스 애시도필러스 hy7037 및 이를 유효성분으로 함유하는 제품 | |
KR20230026096A (ko) | 줄기세포 유래 세포외소포체를 유효성분으로 포함하는 조성물 | |
JP2024033343A (ja) | 乳酸菌発酵物含有組成物 | |
JP2002255853A (ja) | 免疫賦活組成物 | |
JP2024033344A (ja) | 乳酸菌発酵物含有組成物 | |
CN117257733A (zh) | 一种骨靶向益生菌外囊泡及其制备方法 | |
KR20140021391A (ko) | 디벤자제핀을 포함하는 골 대사성 질환 예방 또는 치료용 약제학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 531377 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027004619 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 79473/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000969840 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2388243 Country of ref document: CA Ref document number: 008145660 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027004619 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10110206 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000969840 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 79473/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000969840 Country of ref document: EP |